Relay Medical Commences User Studies on Pharmatrac Medication Management Technology
Toronto, Ontario--(Newsfile Corp. - November 20, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), an engine of MedTech innovation, is pleased to announce the commencement of user studies on the Company's wholly-owned Pharmatrac medication management technology. In conjunction, Relay Medical has engaged the research and systems design firm Human Factors North Inc. (HFN) to design and manage the Toronto, Ontario based user studies. The user study is...
2018-11-20 4:29 PM EST
Relay Medical Introduces the Pharmatrac Technology and Reports on Development
Toronto, Ontario--(Newsfile Corp. - November 15, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), an engine of MedTech innovation, is pleased to introduce the Company's Pharmatrac Technology and report on related development activities. The Pharmatrac is a UX-centric (user experience) system designed to improve management and identification of medications. The Pharmatrac technology was acquired as part of Relay's recent acquisition of the Ottawa...
2018-11-15 3:05 AM EST
Relay Medical Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 13, 2018) - Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), an engine of MedTech innovation, is pleased to report on two propriety software developments and the expansion of the Company's headquarters and development facilities. The software developments include a cloud-based regulatory management system and a modular software development toolkit for rapid prototyping and proprietary development. Relay's...
2018-11-13 3:05 AM EST
Relay Medical To Commence Trading in United States as RYMDF
Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), an engine of MedTech innovation, is pleased to provide an update on the Company's trading status in the United States. On September 25, 2018, Relay Medical will commence trading on the OTC:QB market under the symbol RYMDF. Relay currently trades on the Canadian Securities Exchange in Canada as RELA and in Europe under the symbol EIY2. For further...
2018-09-24 9:58 PM EDT
Relay Medical Signs Term Sheet for New Product Acquisition
Toronto, Ontario--(Newsfile Corp. - August 23, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: CHXIF) (FSE: EIY2) ("Relay" or the "Company"), a developer of MedTech innovation, is pleased to announce the signing of a term sheet to acquire a gynecological clinical invention. The invention addresses postoperative gynecological complications and is intended to address a clear clinical need and a very large market. This acquisition represents an opportunity for product development in-line with...
2018-08-23 4:05 PM EDT
Letter from Lahav Gil, Relay Medical CEO
Toronto, Ontario--(Newsfile Corp. - August 8, 2018) - Relay Medical Corp. (the "Company" or "Relay") (CSE: RELA) (OTC: CHXIF) (FSE: EIY2) (WKN: A2JQR0) is pleased to release the following letter from Lahav Gil, Company CEO. From the desk of Lahav Gil, Chief Executive Officer, Relay Medical Corp.: Dear Shareholders, As we enter this new phase in business expansion, I would like to take this opportunity to address our shareholders, supporters and the investing public at large, to provide...
2018-08-08 4:08 PM EDT
Relay Medical Announces Completion of Private Placement Raising Aggregate Gross Proceeds of $2,251,200.44
Toronto, Ontario--(Newsfile Corp. - August 3, 2018) - Relay Medical Corp. ("Relay" or the "Company") (CSE: RELA) (OTCQB: CHXIF) (FSE: EIY2), a developer of MedTech innovation, is pleased to announce that the Company has completed the second and final tranche (the "Second Tranche") of the placement offering (the "Offering") for gross proceeds of $640,000.76 through the issuance of 2,782,612 units (each, a "Unit") at a price of $0.23 per Unit. The aggregate gross proceeds raised pursuant to the...
2018-08-03 4:05 PM EDT
Relay Medical Provides HemoPalm Update
Toronto, Ontario--(Newsfile Corp. - August 3, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: CHXIF) (FSE: EIY2) ("Relay" or the "Company"), a developer of MedTech innovation, is pleased to provide an update on recent development activities related to the Company's HemoPalm product. In early January 2018, Lahav Gil was appointed Chief Executive Officer. Lahav has since led the expansion of the Company's development infrastructure and techno-commercial team to conduct thorough market research...
2018-08-03 3:00 AM EDT
Relay Medical Announces Closing of Private Placement for Proceeds of Over $1.6M
Toronto, Ontario--(Newsfile Corp. - July 27, 2018) - Relay Medical Corp. (CSE: RELA) (OTCQB: CHXIF) (FSE: EIY2) ("Relay" or the "Company"), a developer of MedTech innovation, is pleased to announce that the Company has closed a private placement offering (the "Offering") for gross proceeds of $1,611,199.68 through the issuance of 7,005,216 units (each, a "Unit") at a price of $0.23 per Unit. Each Unit is comprised of: (i) one common share in the capital of the Company (a "Common Share"); (ii)...
2018-07-27 4:05 PM EDT
ChroMedX Announces Results of Annual General Meeting and Name Change
Toronto, Ontario--(Newsfile Corp. - July 4, 2018) - ChroMedX Corp., (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the results of the annual general meeting held on June 29, 2018. All matters presented to the shareholders were approved including the change of the Company's name to Relay Medical Corp. In accordance with the Company's expansion into an integrated Medtech accelerator/incubator, as...
2018-07-04 4:54 PM EDT
ChroMedX Appoints Tom Glawdel as Chief Scientific Officer and HemoPalm Science Lead
Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Tom Glawdel, PhD as Chief Scientific Officer and HemoPalm science lead effective immediately. Mr. Glawdel is a decorated PhD in Mechanical and Mechatronics Engineering from the University of Waterloo with experience in the development of microfluidic, molecular...
2018-06-20 4:10 PM EDT
ChroMedX Announces Expansion and Launch as Relay Medical Corp.
Toronto, Ontario--(Newsfile Corp. - June 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on the Company's expansion into a Medtech incubator/accelerator platform and launch as Relay Medical Corp. The formal name change will take place following the Company's Annual General Meeting on June 29, 2018. Since his appointment as CEO in January 2018, Lahav Gil has led the build-out of...
2018-06-19 4:10 PM EDT
ChroMedX Acquires UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 24, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the closing of its previously announced acquisition (the "Transaction") of the Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD"). "The depth and breadth of the UXD vision and technology promises to change the paradigm for medication from linear to matrix,...
2018-05-24 7:36 PM EDT
ChroMedX Signs Deal to Acquire UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 9, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that it has entered into a binding Letter-of-Intent ("LOI") to acquire Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD"). UX Data Sciences Corp. is a private Ottawa-based medical technology and data science company developing UX-centric products and systems...
2018-05-09 11:41 AM EDT
ChroMedX Reports on HemoPalm Techno-Commercial Analysis and Productization Plan
Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on HemoPalm activities. In early January 2018, ChroMedX announced the appointment of Lahav Gil as Chief Executive Officer and Director. Since that time Lahav has led the expansion of the Company's development infrastructure and team to conduct a techno-commercial analysis and feasibility study...
2018-05-08 9:13 AM EDT
ChroMedX Appoints Michaela Shaw as Director of Quality Assurance and Regulatory Assurance
Toronto, Ontario--(Newsfile Corp. - April 13, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Michaela Shaw as Director of Quality Assurance and Regulatory Assurance. As Director of QA/RA Ms. Shaw's immediate mandate is to accelerate the Company's QMS towards ISO 13485 compliance by Q2 2019, as the Company expands its team, scope, and projects. "I have worked...
2018-04-13 4:05 PM EDT
ChroMedX CEO Lahav Gil Invited to Speak on Industry Panel at bioTEC, Biotechnology and Bioengineering Conference
Toronto, Ontario--(Newsfile Corp. - March 27, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") , developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that CEO Lahav Gil will speak at the 2018 bioTEC Conference at the University of Waterloo to discuss innovation culture and Medtech commercialization. Lahav is an invited speaker on the industry panel at the bioTEC Biotech and Bioengineering Conference, the first of its kind in Canada....
2018-03-27 4:35 PM EDT
ChroMedX Accelerates Software Development and Implementation Activities; Appoints iGAL Roytblat, Formerly of Kangaroo Group, as CTO, Amid Expansion
Toronto, Ontario--(Newsfile Corp. - March 21, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce an update on the acceleration of software development and implementation activities led by newly appointed Chief Technology Officer (CTO) iGAL Roytblat. The new HemoPalm Software Architecture is built on a scriptable engine with visual authoring tools that enable an accelerated R&D cycle,...
2018-03-21 6:27 PM EDT
ChroMedX Appoints Raj Kailasanathan as Executive Vice President Corporate Finance
Toronto, Ontario--(Newsfile Corp. - March 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Raj Kailasanathan as ChroMedX Corp. Executive Vice President, Corporate Finance. Mr. Kailasanathan joins ChroMedX as a seasoned finance executive with over 20 years experience in the private and public industry in Asia and North America. Prior to joining ChroMedX Corp.,...
2018-03-19 4:05 PM EDT
ChroMedX CEO Lahav Gil Assembles Task-Force to Explore Feasibility and Applications of Automated Ultrafiltration Technology
Toronto, Ontario--(Newsfile Corp. - February 15, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the formation of an evaluation team for the analysis of the Company's patented Automated Ultrafiltration Technology (AUF). The AUF technology will allow fast, automated preparation of ultra-filtrates of serum and plasma samples, for measurement of free therapeutic drugs and hormones. The...
2018-02-15 4:05 PM EST